medcelerator · clinician one-pager
New Pill Option for Kidney Disease in Adults With Type 1 Diabetes
Kerendia (finerenone) — once-daily oral pill to lower urine protein in adults with kidney disease and type 1 diabetes
FDA Approved · United States · September 18, 2026
Condition: Type 1 Diabetes with CKD
Who this is for
This is for adults with type 1 diabetes who already have chronic kidney disease with protein in the urine and may be candidates for labelled US Kerendia as a once-daily oral add-on on top of ACE inhibitor or ARB care — now with a dedicated T1D CKD indication based on FINE-ONE. It explains the September 2026 FDA expansion, the UACR results and what “expected” kidney-outcome language means, potassium monitoring, Bayer support contacts, and how to talk with a diabetes / kidney clinician — without treating a urine-protein drop as a proven end-stage-kidney-disease cure in T1D, collapsing the type 2 or heart-failure labels into this pathway, a DIY import as a plan, or “approved” as funded. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/kerendia-finerenone-t1d-ckd